As described above, HNRNPA1 could serve as a therapeutic target in breast cancer, consistent with the Kaplan–Meier analysis showing that high HNRNPA1 levels were associated with poor clinical outcomes in basal-like breast cancer. Here, HNRNPA1 is linked to breast cancer.